Cognition Therapeutics, Inc. reported its financial results for the first quarter ended March 31, 2025, with cash and cash equivalents at approximately $16.4 million. The company also noted $47.0 million in obligated grant funds remaining from the National Institute of Aging.
The company estimates that its current cash and grant funds are sufficient to fund operations and capital expenditures into the fourth quarter of 2025. Research and development expenses for the quarter were $10.8 million, a slight increase from $10.6 million in the comparable period of 2024, driven by increased Phase 2 trial activities.
Cognition reported a net loss of $8.5 million, or $(0.14) per basic and diluted share, for the first quarter of 2025. The company has requested an end-of-Phase 2 meeting with the FDA for Alzheimer’s disease and initiated the process to secure a commercial investigational new drug (IND) application for zervimesine in dementia with Lewy bodies to facilitate a separate EOP2 meeting for that indication.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.